Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GBT Global Blood Therapeutics	$68.49	$68.47	$21.65 ▼ $73.02	$4.62B	0.45	2.07 million shs	74 shs
IMAB I-Mab	$2.29 -2.1%	$1.59	$0.60 ▼ $3.08	$191.09M	1.4	388,594 shs	485,354 shs
OPK OPKO Health	$1.34 +0.8%	$1.33	$1.19 ▼ $2.04	$1.05B	1.34	3.86 million shs	2.67 million shs
RCKT Rocket Pharmaceuticals	$2.88 +11.2%	$4.68	$2.19 ▼ $26.98	$276.58M	0.67	2.19 million shs	5.60 million shs
TARO Taro Pharmaceutical Industries	$42.97	$42.83	$32.67 ▼ $45.76	$1.62B	0.56	45,199 shs	N/A

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GBT Global Blood Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
IMAB I-Mab	-2.14%	-17.63%	+78.91%	+213.66%	+44.94%
OPK OPKO Health	+0.75%	+5.51%	-2.90%	-14.65%	+10.74%
RCKT Rocket Pharmaceuticals	+11.20%	+8.68%	+3.97%	-48.20%	-85.44%
TARO Taro Pharmaceutical Industries	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GBT Global Blood Therapeutics	0.2616 of 5 stars	0.0	0.0	0.0	4.0	0.0	0.0	0.6
IMAB I-Mab	3.0597 of 5 stars	3.7	3.0	0.0	0.0	2.9	1.7	0.6
OPK OPKO Health	4.4645 of 5 stars	3.4	2.0	0.0	4.4	1.5	5.0	0.6
RCKT Rocket Pharmaceuticals	4.9137 of 5 stars	4.2	2.0	0.0	4.7	2.8	5.0	1.3
TARO Taro Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GBT Global Blood Therapeutics	0.00	N/A	N/A	N/A
IMAB I-Mab	3.33	Buy	$6.00	162.01% Upside
OPK OPKO Health	2.75	Moderate Buy	$2.75	105.22% Upside
RCKT Rocket Pharmaceuticals	2.41	Hold	$18.60	545.83% Upside
TARO Taro Pharmaceutical Industries	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest RCKT, IMAB, GBT, OPK, and TARO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $5.00
6/17/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
6/3/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $11.00
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
5/28/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00
5/28/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell
5/28/2025	RCKT Rocket Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$37.00 ➝ $8.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GBT Global Blood Therapeutics	$194.75M	23.73	N/A	N/A	$3.05 per share	22.46
IMAB I-Mab	$3.89M	48.07	N/A	N/A	$2.47 per share	0.93
OPK OPKO Health	$713.10M	1.49	$0.07 per share	19.33	$2.00 per share	0.67
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.08 per share	N/A
TARO Taro Pharmaceutical Industries	$629.18M	2.57	$2.38 per share	18.03	$47.70 per share	0.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GBT Global Blood Therapeutics	-$303.09M	-$5.01	N/A	N/A	N/A	-137.30%	-170.37%	-39.24%	N/A
IMAB I-Mab	-$22.23M	N/A	0.00	N/A	N/A	N/A	-19.81%	-18.63%	8/27/2025 (Estimated)
OPK OPKO Health	-$53.22M	-$0.07	N/A	N/A	N/A	-5.66%	-2.85%	-1.82%	8/6/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.63	N/A	N/A	N/A	N/A	-64.92%	-56.13%	8/4/2025 (Estimated)
TARO Taro Pharmaceutical Industries	$53.87M	$1.44	29.84	∞	N/A	8.56%	3.75%	3.09%	N/A

Latest RCKT, IMAB, GBT, OPK, and TARO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A
4/30/2025	Q1 2025	OPK OPKO Health	-$0.07	-$0.10	-$0.03	-$0.10	$163.13 million	$149.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GBT Global Blood Therapeutics	N/A	N/A	N/A	N/A	N/A
IMAB I-Mab	N/A	N/A	N/A	N/A	N/A
OPK OPKO Health	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TARO Taro Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GBT Global Blood Therapeutics	4.92	6.88	6.17
IMAB I-Mab	N/A	22.35	22.35
OPK OPKO Health	0.25	2.49	2.28
RCKT Rocket Pharmaceuticals	0.05	9.19	9.19
TARO Taro Pharmaceutical Industries	N/A	3.61	3.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GBT Global Blood Therapeutics	N/A
IMAB I-Mab	38.38%
OPK OPKO Health	64.63%
RCKT Rocket Pharmaceuticals	98.39%
TARO Taro Pharmaceutical Industries	91.40%

Insider Ownership

Company	Insider Ownership
GBT Global Blood Therapeutics	4.90%
IMAB I-Mab	22.10%
OPK OPKO Health	49.69%
RCKT Rocket Pharmaceuticals	24.76%
TARO Taro Pharmaceutical Industries	13.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GBT Global Blood Therapeutics	457	67.48 million	64.17 million	Optionable
IMAB I-Mab	380	81.66 million	63.61 million	Optionable
OPK OPKO Health	2,997	793.05 million	398.99 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	80.35 million	Optionable
TARO Taro Pharmaceutical Industries	1,554	37.59 million	32.40 million	Optionable

RCKT, IMAB, GBT, OPK, and TARO Headlines

Recent News About These Companies

Sun Pharma Q4 preview: Analysts expect 18% jump in profit; check details

May 21, 2025 | business-standard.comB

Sun Pharma Q4 FY25 Preview: Specialty push and domestic growth to lift earnings

May 21, 2025 | moneycontrol.com

Sun Pharma subsidiary acquires Antibe Therapeutics for Rs 27 crores

March 19, 2025 | medicaldialogues.inM

This Pharmaceutical Company Completes 100 per cent Acquisition of Antibe Therapeutics for CAD 4.5 Million

March 19, 2025 | dsij.inD

Sun Pharma to acquire Checkpoint Therapeutics Inc for up to $355 million

March 10, 2025 | thehindubusinessline.com

FDA approves first generics of anticoagulant Xarelto

March 5, 2025 | pharmaphorum.comP

Sun Pharma seeks shareholders' nod for $1 bn related-party transactions

February 20, 2025 | business-standard.comB

Taro to acquire 100% stake in Antibe Therapeutics

January 20, 2025 | thepharmaletter.comT

Sun Pharma unit poised to buy Canadian biotech Antibe

January 19, 2025 | pharmaphorum.comP

Meet Man, started business with only Rs 2000 in one room with 2 employees, son of pharma distributor, now owner of Rs…

November 12, 2024 | msn.com

FINAL REMINDER TARO DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Taro Pharmaceutical Industries Ltd. Investors to Participate in the Class Action Lawsuit!

November 12, 2024 | accesswire.comA

TARO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

November 10, 2024 | globenewswire.com

TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Taro Pharmaceutical Industries Ltd. to Contact the Firm Today!

November 10, 2024 | accesswire.comA

Medicus Pharma readies for IPO as it targets $20B industry

November 8, 2024 | bizjournals.com

TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Taro Pharmaceutical Industries Ltd. to Contact the Firm Today!

November 8, 2024 | accesswire.comA

TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Taro Pharmaceutical Industries Ltd. to Contact the Firm Today!

November 7, 2024 | accesswire.comA

TARO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Shareholders Have Opportunity to Lead Class Action Lawsuit!

November 5, 2024 | accesswire.comA

TARO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

November 4, 2024 | globenewswire.com

TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Stockholders Have Opportunity to Lead Class Action Lawsuit!

November 4, 2024 | accesswire.comA

TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Shareholders Have Opportunity to Lead Class Action Lawsuit!

November 3, 2024 | accesswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT, IMAB, GBT, OPK, and TARO Company Descriptions

Global Blood Therapeutics NASDAQ:GBT

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

I-Mab NASDAQ:IMAB

$2.29 -0.05 (-2.14%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$2.31 +0.02 (+0.66%)

As of 06:07 AM Eastern

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

OPKO Health NASDAQ:OPK

$1.34 +0.01 (+0.75%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$1.35 +0.01 (+0.75%)

As of 06:35 AM Eastern

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Rocket Pharmaceuticals NASDAQ:RCKT

$2.88 +0.29 (+11.20%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$2.93 +0.05 (+1.74%)

As of 06:12 AM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Taro Pharmaceutical Industries NYSE:TARO

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time